Neurological complications in plasma cell dyscrasias

Bayat, Elham; Kelly, John J.

doi:10.1016/b978-0-444-53502-3.00020-3

Cited by 8 publications

(3 citation statements)

References 160 publications

(165 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peripheral neuropathy is common and is frequently associated with plasma cell dyscrasias, which may correspond to 10% of patients with idiopathic peripheral neuropathy and as high as 20% in patients with multiple myeloma. In this study, a high neurological compromise was found, with paresis of the lower limbs more frequent 24,25 . Bone lesions visualized on a conventional radiograph, which may include osteolytic lesions or the presence of fractures, are described in 80% of patients at the time of diagnosis.…”

Section: Methodssupporting

confidence: 48%

Plasma cell dyscrasia behavior in a referral hospital in southern Colombia: younger, clinically and paraclinically worse than reported

Buitrago-Toro¹,

Perdomo²,

Panqueva³

et al. 2020

Gal. Clin.

View full text Add to dashboard Cite

Objectives: Plasma cell dyscrasias are diseases characterized by clonal proliferation and accumulation of cells producing monoclonal immunoglobulins. These diseases have not been studied in our region and we don't know if their behavior is similar to that reported in the literature. That's why we evaluated multiple characteristics in southern Colombia. Methods: analytical cross-sectional study of patients with confirmed diagnosis of a plasma cell dyscrasias were included. Results: 60 patients included in our study, 65% were men, with an average age of 58.8 years (CI 96% 55.8 -61.93). Bone pain was the most frequent symptom (88%). The most frequent dyscrasia was multiple myeloma and in these patients we found a high percentage of hemoglobin less than 10 mg/dl, creatinine greater than 2 mg/dl and serum calcium higher than 11 mg/dl (77%, 38% and 37 %, respectively). Half of the patients had a time course of symptoms greater than 4 months and 43% had plasma cells in bone marrow greater than 60%. 65% of patients had elevated levels of serum B2-microglobulin (> 5.5 mg/L) and in-hospital mortality was 15%. We found a statistically significant association between mortality and gender (PR 6.5) and between mortality and hemoglobin (p = 0.039). Conclusion:Patients with plasma cell dyscrasia in southern Colombia are younger, consult late, in an advanced stage of their disease, with greater renal damage, hypercalcemia and anemia than reported in the literature, also a high tumor burden due to high plasma cell infiltration into bone marrow and high values of serum B2-microglobulin.

show abstract

Section: Methodssupporting

confidence: 48%

Plasma cell dyscrasia behavior in a referral hospital in southern Colombia: younger, clinically and paraclinically worse than reported

Buitrago-Toro¹,

Perdomo²,

Panqueva³

et al. 2020

Gal. Clin.

View full text Add to dashboard Cite

show abstract

“…9,12 Paraproteinemias are associated with several different types of neuropathy. 13,14 Furthermore, drug treatment of Waldenstr€ om disease and multiple myeloma may involve the use of CIPN-causing medications (proteasome inhibitors, thalidomide, and related analogues), which can further complicate the determination of the etiology of the neuropathy. Bone marrow transplantation resulting in graft versus host disease can be associated with neuropathies such as Guillain-Barr e syndrome and CIDP.…”

Section: Approach To Peripheral Neuropathy In Patients With Cancermentioning

confidence: 99%

“…Direct neoplastic infiltration may occur in neurolymphomatosis, leukemia, and rarely carcinoma, and may mimic chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) . Paraproteinemias are associated with several different types of neuropathy . Furthermore, drug treatment of Waldenström disease and multiple myeloma may involve the use of CIPN‐causing medications (proteasome inhibitors, thalidomide, and related analogues), which can further complicate the determination of the etiology of the neuropathy.…”

Section: Approach To Peripheral Neuropathy In Patients With Cancermentioning

confidence: 99%

Chemotherapy‐induced peripheral neuropathy: A current review

Staff

Grisold

et al. 2017

Annals of Neurology

589

389

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30–40% of patients treated with neurotoxic chemotherapy will develop CIPN and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents.

show abstract

Tools

Feldman

Grisold

2014

Atlas of Neuromuscular Diseases

View full text Add to dashboard Cite

Neurological complications in plasma cell dyscrasias

Cited by 8 publications

References 160 publications

Plasma cell dyscrasia behavior in a referral hospital in southern Colombia: younger, clinically and paraclinically worse than reported

Plasma cell dyscrasia behavior in a referral hospital in southern Colombia: younger, clinically and paraclinically worse than reported

Chemotherapy‐induced peripheral neuropathy: A current review

Tools

Contact Info

Product

Resources

About